The plasma of uremic patients usually contains high concentrations of the so-called middle molecules (molecular mass, 300 to 1500 Da), which exert various toxic effects. Among these numerous substances, only one, named peak b4-2, has been correlated with uremic neuropathy. We describe our improvement of a two-stage chromatographic method, gel permeationfollowedby anion-exchange chromatography (J. Chromatogr. 146: [55][56][57][58][59][60][61][62][63][64][65] 1978), for separation and quantification of b4-2 in body fluids. In analyzing more than 300 samples from 43 uremic patients and 12 healthy subjects, we founda linear correlation between peak area at 254 nm and b4-2 concentration in the range 0.8 to 32 mg/L. The coefficient of variation, including data acquired during seven changes of columns, was 9%. Analysis time (80 mm) was shorter than required with other methods. Our results confirm previous data for urinary b4-2 excretion by healthy subjects and for b4-2 removal rate in uremic patients undergoing hemodialysis or hemofiltration. Patients treated with continuous ambulatory peritoneal dialysis have a higher b4-2 excretion than do healthy subjects, suggesting a higher production of this solute in uremic patients. 
"middle molecules" (3). These actions were shown mainly in in vitro experiments such as inhibition of induced lymphocyte proliferation, inhibition of platelet release, inhibition of the growth of cultured mouse 3T3 fibroblasts, inhibition of the frog aural nerve action potential, and inhibition of phagocytosis (4) (5) (6) (7) (8) .
Polyneuritis is a principal symptom of middle molecule retention in uremic patients. Two of us treated six patients with a dialysis strategy involving a high removal rate for middle molecules, by using a high-permeability membrane (AN-69; Rh#{244}ne-Poulenc, Vitry, France) (9). The neurological status of all these patients improved after three months of adequate dialysis (10); however, this improvement was found to be correlated only with a decrease in the concentration in plasma of a middle molecule named peak b4-2 (11), the in vitro neurotoxicity of which has been proved by the frog sural nerve test (12). Cueille described a two-stage chromatographic procedure for measuring b4-2 in body fluids (13).
We describe a modification of Cueille's method. Our procedure allows better recovery of peak b4-2, and substantial reduction of the coefficient of variation for peak surface area, thus improving reproducibility. Analysis time is shorter than required by FUrst et al. (14) and by Chapman et al. (15) for quantifying other uremic middle molecules (peak 7c) by gel-permeation chromatography followed by ion-exchange chromatography. This improved method allowed us to evaluate the peritoneal and renal excretion of the toxin b4-2 in uremic patients treated with continuous ambulatory peritoneal dialysis, as compared with urinary excretion in healthy subjects. Figure 1 shows the chromatographic system we used. 
Materials and Methods

Apparatus
Procedures
Chromatography.
All the analyses were run at room temperature.
For the steric-exclusion column (Sephadex G 15), pressure was continuously checked and kept within the range 25 to 100 kPa. Elution volume(ml) that solute b4-2 isolated from the urine of healthy subjects was the same as that isolated from the hemoffitrate of uremic patients (18). Its purity was checked by ion-exchange chromatography, thin-layer chromatography with various detection methods, ultraviolet absorbance at 206 nm and 254 nm in ethanol, infrared spectrum, proton nuclear magnetic resonance spectrum in D6-dimethyl sulfoxide, and 13C nuclear magnetic resonance spectrum in deuterated water (11) . Preliminary data obtained by mass spectrometry showedthat b4-2 is a glucuronide with a relative molecular mass of 568 (or 526 in native form) (19). The chemical structure of the aglycon moiety remains to be elucidated.
In the present work the b4-2 we used as a standard came from the material used for structure determination by mass spectrometry
(19).
Calculations. The b4-2 peak area was calculated by multiplying the height by the half-height width. Results were compared with the peak area of the standard b4-2 purified from the urine of healthy subjects (final concentration, 21 mgfL) to determine the concentration in the samples. 
A linear
standard curve (y = 0.257 + 0.366x) was obmined by plotting peak area (cm2)
Patients
Healthy subjects. We assayed plasma and 24-h urines of healthysubjects on a free diet.
Hemodialysis.
Plasma and hemodialysate came from uremic patients submitted to regular hemodialysis treatment three times a week with a closed batch-dialysate delivery system (Cuprophan hemodialyzer, 1.8 m2 effective surface).
Hemofiltration. Hemoffitration (three times a week) was performed with a Filtral hemodialyzer, and b4-2 was measured in the pooled hemofiltrate from one session.
Peritoneal dialysis. Seven patients treated with continuous ambulatory peritoneal dialysis according to the technique of Oreopoulos et al. (20) for 120-575 days were admitted for mass balance study. The patients, in stable clinical condition, had creatinine clearances ranging from 1.1 to 7.4 mL/min per 1.73 square meters of body surface. Blood samples were withdrawn at the beginning and at the end of the 24-h study period. Bags of fresh and used dialysate were carefully weighed for mass balance. Peritoneal dialysate flow rates were in the range 4.1-6.9 mllmin. Used dialysates were pooled for each patient, well mixed, and sampled for b4-2 determination; 24-h urines were collected for the same purpose.
Results
Analysis time. A whole run was completed in less than 80 nun.
Precision. The reproducibility of the method was checked in two ways. First, the within-day CV for retention volume of b4-2 was 1.9% (n = 11). Secondly, reproducibility among runs was followed from September 1980 to August 1981. Repeated injections of the same amount of purified b4-2 corresponded to a mean peak area of 74 (SD 3.1) cm2/mL injected (n = 23, CV = 4.2%). For the same period the surface area given by one specific sample (100 jtL of fivefold diluted urine from a healthy subject) was 8.0 (SD 0.7) cm2! mL (n = 15, CV = 9.0%). Retention volumes were 12.14 (SD 0.70) mL (n = 23) and 12.26 (SD 0.62) mL (n = 15), respectively, for purified b4-2 and for the urine sample. This one-year period included seven changes of columns and more frequent changesof buffers.
Detection limit. Taking into account the baseline perturbations occurring at the sensitivity scale we used, no accurate quantification could be made at concentrations less than 0.8 mgIL, owing the nonlinearity of the calibration curve in this concentration range (not shown). Practically, this corresponded to a minimal amount of 0.4 pg of b4-2 (in 500 pL) that could be applied to the top of the column.
Accuracy. Urine from a healthy subject was diluted twoto 40-fold with water. Measured concentrations of the 10 diluted samples (over the 40-fold concentration range) were plotted against theoretical dilution values, giving a linear correlation (y = 0.168 + 31.12x, r = 0.998, n = 11) in the range of 0.8 to 32 mgfL (not shown). Furthermore, after correction for dilution, mean ± SD was 32.0 ± 1.3 mgfL, for a CV of less than 4%. Analyses were in fact run in the range 2-21 mgIL.
Potential interferences. Peak b4-2 being correlated with neuropathy, we focused our attention on artifacts that could impede its accurate quantification, especially the peaks immediately preceding and following it (b4-1 and b5) . More than 300 samples were analyzed (from 43 patients and 12 healthy subjects) and checked for the presence of a high peak b4-1 or b5 (i.e., peak b4-2) . Apparently such interference could be related either to the preparation of the samples or to the drugs the patients were receiving. For example, acetylsalicylic acid, ingested orally, produced a high peak b5 in the urine of healthy subjects and in the dialysate of uremic patients. Neither the use of sodium azide (NaN3) as preservative in hemodialysate, urine, or hemofiltrate, nor the use of heparin as anticoagulant caused artifactual peaks. Blood samples collected into tubes containing fluoride + oxalate, however, gave a high peak b5. In peritoneal dialysate that was not deproteinized by ultrafiltration on AN-69, a higher peak b3 was observed. By not allowing accurate estimation of the baseline, this impeded calculation of the area of peak b4-2. Hemolysate, which is known to contain middle molecules (15, 21) , was found to give a very high peak b4-1. Erythrocyte middle molecules had an elution volume close to that of b4-2. When whole blood was analyzed after complete hemolysis, it was not possible to measure peak b4-2 accurately because the erythrocytes absorbed strongly at 254 nm. However, erythrocytes do not seem to contain a significant amount of peak b4-2.
Evaluation of b4-2 excretion. Table 1 shows b4-2 concentration in plasma and the excretion rate obtained for healthy subjects and for uremic patients treated with hemodialysis or hemofiltration (predialysis values). In the plasma of healthy subjects, the b4-2 concentration remained below the detection limit of the method (<0.8 mg/L). Expressed in terms of standard body surface area, the daily urinary excretion in healthy subjects was 36 ± 2 mg/1.73 m2.
In plasma of seven patients undergoing continuous ambulatory peritoneal dialysis, b4-2 concentration . This improvement could be explained by the fact that the peak b is collected separately (seeFigure 1) at atmospheric pressure and then re-injected on the ion-exchange column at the same flow rate as the gradient is eluted. This allowsaccuratecollection and adequate re-injection of peak b.
The detection limit does not enable precise quantification in healthy subjects of plasma b4-2 concentrations less than 0.8 mg/L, so that preliminary concentration of plasma Healthysubjects(n = 9)
Uremic patients
Hemodialysis (n = 6) (Cuprophanmembrane) Hemofiltration (n = 7) (AN-69 membrane) aMean ± SEM. ultrallltrate is required. However, this sensitivity is quite sufficient for quantifying b4-2 in uremic plasma, hemoffitrate, urine (healthy and uremic subjects), and peritoneal dialysate. Furthermore, hemodialysates, which are sometimes very dilute, can be readily concentrated under reduced pressure, thus enhancing the detection limit.
In our method, preventing artifactual peaks requires some simple precautions in collecting samples. We use lithium heparinate as the anticoagulant, carefully deproteinize plasma and peritoneal dialysate by ultrafiltration through polyacrylonitrile membrane, and avoid hemolysis.
Having checked the reliability of our improved method for separation and quantification of b4-2, we measured the concentration of this solute in healthy subjects and in uremic patients treated with various dialysis strategies. The b4-2 concentration in plasma and the removal rate in uremic patients treated by hemodialysis or hemofiltration compare quite well with our previous results (10). However, the urinary excretion from healthy subjects exceeds the previously reported values. This could be explained by (a) the healthy subjects' receiving an uncontrolled free diet, (b) a more adequate collection of peak b, and/or (c) our reanalysis, after dilution, of those samples having too high a middle molecule concentration, which gave too great a peak b.
Study of continuous ambulatory peritoneal dialysis patients showed that b4-2 concentrations in plasma were not different from predialysis values for patients treated with conventional hemodialysis or hemoffitration. Assuming that total daily excretion (i.e., peritoneal dialysate + urine) reflects the rate of synthesis, the difference between continuous ambulatory peritoneal dialysis patients and healthy subjects suggests that b4-2 production could be greater in uremic patients than in nonuremic individuals.
With the continuous dialysis technique, clearances are partly limited by dialysate flow rate, which is very low compared with intermittent peritoneal dialysis (23) . Thus, in continuous ambulatory peritoneal dialysis patients, increasing the flow rate could possibly improve b4-2 removal and decrease its concentration in plasma.
In conclusion, our modified method for the measurement of b4-2 in body fluids improves the reproducibility and reliability of the quantification. Our data confirm the previous results (10) obtained for uremic patients treated with hemodialysis or hemofiltration. Moreover, the removal rate study in patients treated with continuous ambulatory peritoneal dialysis suggests that our method can be used routinely for assessment of dialysis adequacy.
